Company Overview

NeuroPace, Inc. is a U.S.-based medical technology company focused on the treatment of drug-resistant epilepsy through implantable neuromodulation systems. The company operates within the neuromodulation and medical devices industries, specifically targeting patients whose seizures are not adequately controlled by anti-epileptic medications and who are not candidates for curative epilepsy surgery. NeuroPace’s core offering is a responsive, closed-loop neurostimulation system designed to detect abnormal brain activity and deliver targeted electrical stimulation to reduce seizure frequency.

The company’s primary revenue driver is the sale of its proprietary RNS® System, which includes an implantable neurostimulator, leads, and associated physician programming and monitoring tools. NeuroPace serves specialized epilepsy centers, hospitals, and neurologists, primarily treating adult patients with focal epilepsy. Its unique positioning lies in its FDA-approved closed-loop technology, which continuously monitors brain signals and responds in real time, differentiating it from open-loop neuromodulation systems. NeuroPace was founded in 1997 and evolved through extensive clinical development before receiving FDA approval for the RNS System in 2013, followed by commercialization and an initial public offering in 2021.

Business Operations

NeuroPace operates primarily through a single integrated business focused on the development, manufacturing, and commercialization of implantable neuromodulation devices. Revenue is generated through sales of the RNS® System, including implantable components and related accessories, as well as ongoing support services provided to epilepsy treatment centers. The company maintains control over core intellectual property, device design, and clinical data infrastructure that supports physician use and long-term patient management.

Commercial operations are concentrated in the United States, where the RNS System has regulatory approval and established reimbursement pathways. Internationally, NeuroPace has pursued limited market development through regulatory efforts and distributor relationships rather than large-scale direct operations. The company relies on third-party manufacturers for certain components while retaining oversight of quality systems, regulatory compliance, and post-market surveillance. No material joint ventures have been publicly disclosed, though NeuroPace collaborates with academic epilepsy centers for clinical research and long-term outcome studies.

Strategic Position & Investments

NeuroPace’s strategic direction centers on expanding adoption of the RNS System, broadening clinical indications, and leveraging its large, longitudinal brain signal dataset to enhance device performance and clinical outcomes. Growth initiatives include increasing penetration in U.S. epilepsy centers, improving physician training and awareness, and pursuing additional regulatory approvals for expanded patient populations or geographic markets.

The company has invested significantly in clinical research, including long-term outcome studies demonstrating sustained seizure reduction, which supports payer reimbursement and clinician confidence. NeuroPace has not historically pursued large-scale acquisitions; instead, it focuses on internal research and development to enhance device capabilities, software analytics, and data-driven insights. Emerging areas of interest include advanced signal processing, personalized neurostimulation algorithms, and potential applications of its technology platform beyond epilepsy, though publicly available data on non-epilepsy indications remains limited.

Geographic Footprint

NeuroPace is headquartered in the United States, with its principal executive offices located in California. The company’s commercial footprint is predominantly U.S.-focused, reflecting regulatory approval status, reimbursement infrastructure, and the concentration of comprehensive epilepsy centers within the country.

Internationally, NeuroPace has a limited but growing presence, primarily through regulatory approvals and distribution partnerships in select markets outside the U.S. Its global influence is largely clinical and academic, supported by published studies and collaborations with epilepsy specialists worldwide rather than extensive direct sales operations across continents.

Leadership & Governance

NeuroPace is led by an executive team with experience in medical devices, neuromodulation, and regulated healthcare markets. The leadership emphasizes evidence-based medicine, long-term clinical data generation, and disciplined commercialization within a highly regulated environment. Governance practices align with U.S. public company standards following its listing on the NASDAQ.

Key executives include:

• Michael K. Onuscheck – President and Chief Executive Officer
• Matthew D. Christensen – Chief Financial Officer
• Martha J. Morrell – Chief Medical Officer
• Andrew J. Thompson – Chief Technology Officer
• Steven L. Chung – Chief Operating Officer

The company was founded by individuals with academic and clinical backgrounds in neuroscience and engineering, and its leadership philosophy centers on combining clinical rigor with technological innovation to address unmet needs in epilepsy care.